Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation

• Main Authors: Hoa Le Mai, PhD, Michèle Treilhaud, MD, Shani Leviatan Ben-Arye, PhD, Hai Yu, PhD, Hélène Perreault, PhD, Evelyn Ang, PhD, Katy Trébern-Launay, PhD, Julie Laurent, PhD, Stéphanie Malard-Castagnet, PhD, Anne Cesbron, MD, Thi Van Ha Nguyen, PhD, Sophie Brouard, PhD, Lionel Rostaing, MD, Pauline Houssel-Debry, MD, Christophe Legendre, MD, Sophie Girerd, MD, Michèle Kessler, MD, Emmanuel Morelon, MD, Antoine Sicard, MD, Valérie Garrigue, MD, Georges Karam, MD, Xi Chen, PhD, Magali Giral, MD, Vered Padler-Karavani, PhD, Jean Paul Soulillou, MD
• Format: Article
• Language: English
• Published: Wolters Kluwer 2018-04-01
• Series: Transplantation Direct
• Online Access: http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000000772

Background. End-stage renal failure occurs in a substantial number of patients having received a nonrenal transplantation (NRT), for whom a kidney transplantation is needed. The medical strategy regarding the use of immunosuppression (IS) for a kidney graft in patients after an NRT is not well established. The prekidney grafts long-term IS advocates for a mild induction, such as using anti-IL-2R antibodies, whereas addition of new incompatibilities and anti-HLA preimmunization may suggest using stronger IS such as induction by polyclonal antithymocyte globulins (ATG). Methods. We performed Cox multivariate and propensity score analysis of our validated transplant database to study the impact of the type of induction therapy on kidney graft survival of recipients of a kidney graft after NRT. Results. We report here that kidney transplantation after NRT treated with an ATG induction has a poorer outcome (kidney and recipient survival) than that with an anti–IL-2R induction. After accounting for potential baseline differences with a multivariate Cox model, or by adjusting on a propensity score, we found that despite patients having received ATG cumulate more risk factors, ATG appears independently involved. As animal-derived biotherapeutics induce antiglycan antibodies and particularly anti–N-glycolylneuraminic acid (Neu5Gc) IgGs which may activate endothelial cells in patients and grafts, we also investigated the magnitude and the nature of the anti-Neu5Gc elicited by the induction and showed that induction was associated with a shift in anti-Neu5Gc IgG repertoire. Possible reasons and mechanisms of a deleterious ATG usage in these patients are discussed. Conclusions. Our study suggests that ATG induction after a kidney transplantation in recipients already under maintenance IS for a NRT should be used cautiously.